Forty Seven (Forty Seven) Construction In Progress : $0.00 Mil (As of Dec. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Forty Seven Construction In Progress?

Forty Seven Construction In Progress Historical Data

The historical data trend for Forty Seven's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forty Seven Construction In Progress Chart

Forty Seven Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Construction In Progress

Forty Seven Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
Construction In Progress	Get a 7-Day Free Trial								-	-	-	-	-

Forty Seven Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Forty Seven (Forty Seven) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

1490 Oâ€™Brien Drive, Suite A, Menlo Park, CA, USA, 94025

Website

https://www.fortyseveninc.com

Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.

Executives

Dennis Henner	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball	director	C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads	officer: Chief Financial Officer	4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark	director	SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird	director	755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p.	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre	10 percent owner	2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c.	10 percent owner	C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154